Javascript must be enabled to continue!
Validation of RESP and PRESERVE score for ARDS patients with pumpless Extracorporeal Lung Assist (pECLA)
View through CrossRef
Abstract
Background RESP score and PRESERVE score have been validated for veno-venous Extracorporeal Membrane Oxygenation in severe ARDS to assume individual mortality risk. ARDS patients with low-flow Extracorporeal Carbon Dioxide Removal, especially pumpless Extracorporeal Lung Assist, have also a high mortality rate, but there are no validated specific or general outcome scores. This retrospective study tested whether these established specific risk scores can be validated for pumpless Extracorporeal Lung Assist in ARDS patients in comparison to a general organ dysfunction score, the SOFA score. Methods In a retrospective single center cohort study we calculated and evaluated RESP, PRESERVE, and SOFA score for 73 ARDS patients with pumpless Extracorporeal Lung Assist treated between 2002 and 2016 using the XENIOS iLA Membrane Ventilator. 6 patients had a mild, 40 a moderate and 27 a severe ARDS according to the Berlin criteria. Demographic data and hospital mortality as well as ventilator settings, hemodynamic parameters, and blood gas measurement before and during extracorporeal therapy were recorded. Results Pumpless Extracorporeal Lung Assist of mechanical ventilated ARDS patients resulted in an optimized lung protective ventilation, significant reduction of PaCO2, and compensation of acidosis. Scoring showed a mean score of alive versus deceased patients of 3 ± 1 versus -1 ± 1 for RESP (p < 0.01), 3 ± 0 versus 6 ± 0 for PRESERVE (p < 0.05) and 8 ± 1 versus 10 ± 1 for SOFA (p < 0.05). Using receiver operating characteristic curves, area under the curve (AUC) was 0.78 (95 % confidence interval (CI) 0.67 – 0.89, p < 0.01) for RESP score, 0.80 (95 % CI 0.70 – 0.90, p < 0.0001) for PRESERVE score and 0.66 (95 % CI 0.53 – 0.79, p < 0.05) for SOFA score. Conclusions RESP and PRESERVE scores were superior to SOFA, as non-specific critical care score. Although scores were developed for veno-venous ECMO, we could validate RESP and PRESERVE score for pumpless Extracorporeal Lung Assist. In conclusion, RESP and PRESERVE score are suitable to estimate mortality risk of ARDS patients with an arterio-venous pumpless Extracorporeal Carbon Dioxide Removal.
Springer Science and Business Media LLC
Title: Validation of RESP and PRESERVE score for ARDS patients with pumpless Extracorporeal Lung Assist (pECLA)
Description:
Abstract
Background RESP score and PRESERVE score have been validated for veno-venous Extracorporeal Membrane Oxygenation in severe ARDS to assume individual mortality risk.
ARDS patients with low-flow Extracorporeal Carbon Dioxide Removal, especially pumpless Extracorporeal Lung Assist, have also a high mortality rate, but there are no validated specific or general outcome scores.
This retrospective study tested whether these established specific risk scores can be validated for pumpless Extracorporeal Lung Assist in ARDS patients in comparison to a general organ dysfunction score, the SOFA score.
Methods In a retrospective single center cohort study we calculated and evaluated RESP, PRESERVE, and SOFA score for 73 ARDS patients with pumpless Extracorporeal Lung Assist treated between 2002 and 2016 using the XENIOS iLA Membrane Ventilator.
6 patients had a mild, 40 a moderate and 27 a severe ARDS according to the Berlin criteria.
Demographic data and hospital mortality as well as ventilator settings, hemodynamic parameters, and blood gas measurement before and during extracorporeal therapy were recorded.
Results Pumpless Extracorporeal Lung Assist of mechanical ventilated ARDS patients resulted in an optimized lung protective ventilation, significant reduction of PaCO2, and compensation of acidosis.
Scoring showed a mean score of alive versus deceased patients of 3 ± 1 versus -1 ± 1 for RESP (p < 0.
01), 3 ± 0 versus 6 ± 0 for PRESERVE (p < 0.
05) and 8 ± 1 versus 10 ± 1 for SOFA (p < 0.
05).
Using receiver operating characteristic curves, area under the curve (AUC) was 0.
78 (95 % confidence interval (CI) 0.
67 – 0.
89, p < 0.
01) for RESP score, 0.
80 (95 % CI 0.
70 – 0.
90, p < 0.
0001) for PRESERVE score and 0.
66 (95 % CI 0.
53 – 0.
79, p < 0.
05) for SOFA score.
Conclusions RESP and PRESERVE scores were superior to SOFA, as non-specific critical care score.
Although scores were developed for veno-venous ECMO, we could validate RESP and PRESERVE score for pumpless Extracorporeal Lung Assist.
In conclusion, RESP and PRESERVE score are suitable to estimate mortality risk of ARDS patients with an arterio-venous pumpless Extracorporeal Carbon Dioxide Removal.
Related Results
Accuracy of the Radiographic Assessment of Lung Edema Score for the Diagnosis of ARDS
Accuracy of the Radiographic Assessment of Lung Edema Score for the Diagnosis of ARDS
Background: Bilateral opacities on chest radiographs are part of the Berlin Definition for Acute Respiratory Distress Syndrome (ARDS) but have poor interobserver reliability. The “...
Characterizing a focused landscape of familial acute respiratory distress syndrome
Characterizing a focused landscape of familial acute respiratory distress syndrome
Abstract
Background Acute respiratory distress syndrome (ARDS) affects approximately 190,600 patients per year in the United States, with mortality up to 45%. ARDS can occu...
ESM-1 Levels and ARDS Prediction Score for Predicting ARDS Occurrence in Sepsis Patients
ESM-1 Levels and ARDS Prediction Score for Predicting ARDS Occurrence in Sepsis Patients
Abstract
Background: Acute respiratory distress syndrome (ARDS) development is overtly associated with elevated mortality. This study aimed to determine the parameters pred...
Rapidly improving acute respiratory distress syndrome in COVID-19: a multi-centre observational study
Rapidly improving acute respiratory distress syndrome in COVID-19: a multi-centre observational study
AbstractBackgroundBefore the pandemic of coronavirus disease (COVID-19), rapidly improving acute respiratory distress syndrome (ARDS), mostly defined by early extubation, had been ...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
What Is Different in Acute Hematologic Malignancy-Associated ARDS? An Overview of the Literature
What Is Different in Acute Hematologic Malignancy-Associated ARDS? An Overview of the Literature
Background and Objectives: Acute hematologic malignancies are a group of heterogeneous blood diseases with a high mortality rate, mostly due to acute respiratory failure (ARF). Acu...
Impairment of Lung and Chest Wall Mechanics in Patients with Acute Respiratory Distress Syndrome
Impairment of Lung and Chest Wall Mechanics in Patients with Acute Respiratory Distress Syndrome
Abstract
Recent data have suggested that the elastic properties of the chest wall (CW) may be compromised in patients with ARDS because of abdominal distension (4...
Use of Lung Ultrasound for Assessment of Lung Recruitment Maneuvers in Patients with ARDS
Use of Lung Ultrasound for Assessment of Lung Recruitment Maneuvers in Patients with ARDS
BACKGROUND: Positive pressure mechanical ventilation is a non-physiological intervention that saves lives but is not free of important side effects. It invariably results in differ...

